Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02070718 · ClinicalTrials.gov registry record · Phase 1
Effects of a Kappa Agonist on Hot Flashes in Menopausal Women
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02070718 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 12 participants.
The verdict
NCT02070718, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Studies suggest that kappa agonists (KA) and peripherally restricted kappa agonists (PRKAs) may affect thermoregulation. This pilot study has the aim to establish proof of concept regarding efficacy of an oral kappa agonist (KA) for the treatment of menopausal hot flashes.
Interventions
- OTHER Placebo
- DRUG Standard Dose Kappa Agonist
- DRUG Half Dose Kappa Agonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02070718
The ClinicalTrials.gov registry entry for NCT02070718 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02070718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02070718 about?
NCT02070718 is a clinical study titled "Effects of a Kappa Agonist on Hot Flashes in Menopausal Women". Studies suggest that kappa agonists (KA) and peripherally restricted kappa agonists (PRKAs) may affect thermoregulation. This pilot study has the aim to establish proof of concept regarding efficacy of an oral kappa agonist (KA) for the treatment of menopausal hot flashes.
What is the current status of trial NCT02070718?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2013-01. Estimated completion is 2013-07.
What interventions are being tested in trial NCT02070718?
The interventions under investigation include: Placebo (OTHER), Standard Dose Kappa Agonist (DRUG), Half Dose Kappa Agonist (DRUG).
Who is sponsoring clinical trial NCT02070718?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.